Literature DB >> 11096510

Cardiogenic Shock.

.   

Abstract

In the setting of acute myocardial infarction, the timely recognition and treatment of cardiogenic shock are essential in reducing the incidence of death. Patients with cardiogenic shock should be treated aggressively with a combination of pharmacologic agents and mechanical support devices to achieve stabilization. Once stabilization has been achieved, the ultimate goal should be the restoration of flow in the infarct-related artery. This is best achieved with angioplasty or bypass surgery. In those centers not equipped for these procedures, thrombolysis should be performed, and the patient should then be transferred to a higher-level facility.

Entities:  

Year:  2000        PMID: 11096510     DOI: 10.1007/s11936-000-0028-8

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  30 in total

1.  Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival.

Authors:  L Lee; R Erbel; T M Brown; N Laufer; J Meyer; W W O'Neill
Journal:  J Am Coll Cardiol       Date:  1991-03-01       Impact factor: 24.094

Review 2.  The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock.

Authors:  E R Bates; R J Stomel; J S Hochman; E M Ohman
Journal:  Int J Cardiol       Date:  1998-05-29       Impact factor: 4.164

3.  Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock.

Authors:  P J Kovack; M A Rasak; E R Bates; E M Ohman; R J Stomel
Journal:  J Am Coll Cardiol       Date:  1997-06       Impact factor: 24.094

4.  Myocardial changes associated with cardiogenic shock.

Authors:  D L Page; J B Caulfield; J A Kastor; R W DeSanctis; C A Sanders
Journal:  N Engl J Med       Date:  1971-07-15       Impact factor: 91.245

5.  Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

Authors:  D R Holmes; E R Bates; N S Kleiman; Z Sadowski; J H Horgan; D C Morris; R M Califf; P B Berger; E J Topol
Journal:  J Am Coll Cardiol       Date:  1995-09       Impact factor: 24.094

Review 6.  Mechanisms and management of cardiogenic shock.

Authors:  J S Alpert; R C Becker
Journal:  Crit Care Clin       Date:  1993-04       Impact factor: 3.598

Review 7.  Role of intra-aortic counterpulsation in cardiogenic shock and acute myocardial infarction.

Authors:  H S Mueller
Journal:  Cardiology       Date:  1994       Impact factor: 1.869

8.  Improved regional myocardial blood flow, left ventricular unloading, and infarct salvage using an axial-flow, transvalvular left ventricular assist device. A comparison with intra-aortic balloon counterpulsation and reperfusion alone in a canine infarction model.

Authors:  R W Smalling; D B Cassidy; R Barrett; B Lachterman; P Felli; J Amirian
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

9.  Intraaortic balloon counterpulsation with and without reperfusion for myocardial infarction shock.

Authors:  M A DeWood; R N Notske; G R Hensley; J P Shields; W P O'Grady; J Spores; M Goldman; J H Ganji
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

10.  Enhanced coronary blood flow velocity during intraaortic balloon counterpulsation in critically ill patients.

Authors:  M J Kern; F V Aguirre; S Tatineni; D Penick; H Serota; T Donohue; K Walter
Journal:  J Am Coll Cardiol       Date:  1993-02       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.